This inventor holds 9 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 5 EPO patents. Top assignees: Cancer Research Technology Limited, Astrazeneca Ab. Active years: 2018-2023.
Company Filing History:
9 out of 268 
4 out of 1,528 
Years Active: 2018-2023
Title: Mark David Charles: Innovator in Cancer Treatment
Introduction
Mark David Charles is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating cancer. With a total of 9 patents to his name, his work has the potential to impact the lives of many patients suffering from proliferative disorders.
Latest Patents
One of his latest patents is focused on pyrimidinone derivatives as CDC7 inhibitors. This invention relates to compounds that function as inhibitors of the cell division cycle 7 (Cdc7) kinase enzyme activity. The patent also covers pharmaceutical compositions comprising these compounds and their use in treating various diseases, including cancer. Another notable patent involves 1,3,4-thiadiazole compounds, which are designed to treat cancer by inhibiting glutaminase, specifically GLS1.
Career Highlights
Throughout his career, Mark David Charles has worked with notable organizations such as Cancer Research Technology Limited and AstraZeneca. His experience in these companies has allowed him to develop innovative solutions in the pharmaceutical industry.
Collaborations
Mark has collaborated with esteemed colleagues, including Maurice Raymond Verschoyle Finlay and Johannes Wilhelmus Maria Nissink. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Mark David Charles is a dedicated inventor whose work in cancer treatment showcases his commitment to improving healthcare through innovation. His patents reflect a deep understanding of the complexities of cancer and the need for effective treatments.